^
    Back
    Association details:
    Biomarker:IDH1 mutation + WT1 overexpression
    Cancer:Glioblastoma
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Biologics
    Title:

    Sensitivity Assessment of Wilms Tumor Gene ( WT1) Expression in Glioblastoma using qPCR and Immunohistochemistry and its Association with IDH1 Mutation and Recurrence Interval

    Published date:
    07/24/2021
    Excerpt:
    Clinical data were collected from 44 patients with glioblastomas, treated with adjuvant therapies...IDH1mutant cases with WT1 overexpression showed significant difference in RFI (p-value =0.048)….Moreover, IDH1mutant glioblastomas with WT1 overexpression are associated with late RFI particularly if temozolomide with additional chemotherapies are used.
    Secondary therapy:
    Chemotherapy
    DOI:
    10.2147/BTT.S323358